Clinical Research Directory
Browse clinical research sites, groups, and studies.
Oral VK2735 for Weight Management Phase 3 (SUNRISE 1)
Sponsor: Viking Therapeutics, Inc.
Summary
This study is one of two planned Phase 3 studies to support the weight management indication for VK2735 Oral in obese (BMI ≥ 30 kg/m2) or overweight (BMI ≥ 27kg/m2) adults with at least one weight-related comorbidity without type 2 diabetes mellitus.
Official title: A Phase 3 Randomized, Double-Blind, Placebo-Controlled, 68-Week Efficacy and Safety Study of VK2735 Administered Orally for Weight Management in Participants Without Type 2 Diabetes Mellitus Who Are Obese, or Overweight With at Least One Weight-related Comorbid Condition
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
560
Start Date
2026-11
Completion Date
2028-08
Last Updated
2026-10-16
Healthy Volunteers
No
Conditions
Interventions
VK2735
VK2735 Oral is a peptide GLP-1 and GIP dual agonist administered once daily
Placebo comparator
Placebo comparator administered orally once daily